Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse Remitting Multiple Sclerosis
Teriflunomide in multiple sclerosis: Added benefit not proven
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.
Altered intra- and interregional synchronization in relapsing-remitting multiple sclerosis: a resting-state fMRI study.
Synaptic pathology: a shared mechanism in neurological disease.
Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Alkali metals levels in the human brain tissue: Anatomical region differences and age-related changes.
A Complex Case of Neuro-Behçet's Disease in a Patient Previously Diagnosed with multiple Sclerosis: A Case Report.
Treatment Burden and Chronic Illness: Who is at Most Risk?
Retinyl Palmitate Supplementation Modulates T-bet and Interferon Gamma Gene Expression in Multiple Sclerosis Patients.
Burden of neurological conditions in Canada.
Are changes in gait and balance across the Disease Step Rating Scale in Multiple Sclerosis statistically significant and clinically meaningful?
Specific inhibition of secreted NRG1 types I-II by heparin enhances Schwann Cell myelination.
Beta-Interferon, Glatiramer Acetate Cost-Effective in MS
Peripheral Bilateral Telangiectasiae in Multiple Sclerosis Patients Treated with Interferon B1a.
A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.
Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down-regulation of Bcl-xL and XIAP.
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.
A case of multiple evanescent white dot syndrome misdiagnosed as optic neuritis: Differential diagnosis for the neurologist.
Alterations of the optic pathway between unilateral and bilateral optic nerve damage in multiple sclerosis as revealed by the combined use of advanced diffusion kurtosis imaging and visual evoked potentials.
Flupirtine in pain management: pharmacological properties and clinical use.
Evidence for Mitoxantrone-induced Block of Inwardly Rectifying K Channels Expressed in the Osteoclast Precursor RAW 264.7 Cells Differentiated with Lipopolysaccharide.
Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis.
Standing up in multiple sclerosis (SUMS): protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis.
Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases.
Pages
« first
‹ previous
…
79
80
81
82
83
84
85
86
87
…
next ›
last »